ArticleCancer diagnosis & prognosis
Prognostic Significance of Number of Liver Metastases in Patients With Advanced Pancreatic Cancer Receiving Nab-paclitaxel Plus Gemcitabine.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: The prognostic significance of the number of liver metastases in patients with advanced pancreatic cancer (APC) treated with nab-paclitaxel plus gemcitabine (AG) remains unclear. This study was performed to investigate the impact of the number of liver metastases on survival outcomes in this population. Patients and Methods: From January 2015 to July 2024, 103 patients with APC received AG as first-line chemotherapy at Higashiosaka City Medical Center. The patients were categorized into three groups based on contrast-enhanced computed tomography findings: no liver metastases (NLM), several liver metastases (SLM) (1-9), and multiple liver metastases (MLM) (≥10). Overall survival (OS) was estimated using the Kaplan-Meier method and compared using the log-rank test. Patient characteristics and clinical courses were compared between the non-MLM and MLM groups. Prognostic factors were analyzed using Cox regression models. Results: Fifty-two patients were assigned to the NLM group, 23 to the SLM group, and 28 to the MLM group. Median OS was significantly longer in the NLM group (12.0 months) than in the SLM group (9.9 months, Conclusion: The number of liver metastases in patients with APC treated with nab-paclitaxel plus gemcitabine may help stratify prognosis in clinical practice and could serve as a useful parameter for treatment decision making and for stratification in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.